Clinical trials: Obesity
Insulin Resistance, Abdominal Obesity
Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity
The purpose of this study is to demonstrate the efficacy on insulin sensitivity of GFT505 at 80mg/d in male patients with insulin resistance and abdominal obesity. Evaluation will be made using a glucose clamp technique.
- Trial name
- NCT01271777
- Testing
- GFT505 80mg
- Where
- 2 sites in France
- Volunteers
- 22 people
- Sponsor
- Genfit
Healthy
A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)
The goal of this study is to learn about the safety of efinopegdutide (MK-6024) and how well overweight healthy people tolerate it.
- Trial name
- NCT06701305
- Testing
- Efinopegdutide, Acetaminophen
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Overweight, Obesity
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study
The purpose of this study is to determine whether the combination of two dietary supplements: MUSCLE 5, which contains protein, creatine and vitamin D and TRIM 7, which contains beet extract, caffeine, coenzyme Q10, alpha lipoic…
- Trial name
- NCT05384431
- Testing
- Muscle5 and TRIM7, Mixed exercise
- Where
- Canada
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Exerkine Corporation
Obesity
A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833
This is a study to evaluate the safety and efficacy of K-757 alone and in combination with K-833 versus placebo in participants who are obese.
- Trial name
- NCT06019559
- Testing
- K-757 120 mg BID and K-833 100 mg BID
- Where
- 22 sites in United States
- Volunteers
- 155 people
- Sponsor
- TriGemX Bio, Inc.
Overweight and Obesity
A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE103 injection in healthy overweight/obese participants or healthy postmenopausal women.
- Trial name
- NCT07230496
- Testing
- LAE103 injection, LAE102 injection in combined with LAE103 injection, Saline
- Where
- 2 sites in Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Laekna Limited
Prader-Willi Syndrome
Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
This is a multi-center, multi-period study with an open-label period followed by a double-blind, placebo-controlled, randomized withdrawal period evaluating the safety and efficacy of DCCR treatment.
- Trial name
- NCT03714373
- Testing
- DCCR
- Where
- 28 sites in United States, United Kingdom
- Volunteers
- 115 people
- Sponsor
- Soleno Therapeutics, Inc.
Overweight, Obesity
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 3 (NCT03611582)
- Testing
- Semaglutide
- Where
- 41 sites in United States
- Volunteers
- 611 people
- Sponsor
- Novo Nordisk A/S
Pregnancy, Obesity
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
This is an observational cohort study using administrative insurance claims data. The aim of this non-interventional study (NIS) is to compare maternal, fetal and infant outcomes of women exposed to Wegovy during pregnancy to a…
- Conditions
- Pregnancy, Obesity, Overweight
- Trial name
- NCT05503927
- Testing
- No Intervention
- Where
- 2 sites in United States
- Volunteers
- 2,701 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.
- Trial name
- ENLIGHTEN-1 (NCT07321886)
- Testing
- Eloralintide
- Where
- 158 sites in United States, Argentina and 13 more
- Volunteers
- 1,980 people
- Sponsor
- Eli Lilly and Company
Metabolic Syndrome, Pre-diabetes
Effect of Pasteurized Akkermansia Muciniphila on Insulin Resistance in Otherwise Healthy Subjects With Dysglycaemia
The purpose of this study is to demonstrate the efficacy of pasteurized Akkermansia muciniphila (pAKK) in improving insulin sensitivity in hyperglycaemic, but otherwise healthy persons with metabolic syndrome.
- Conditions
- Metabolic Syndrome, Pre-diabetes, Overweight and Obesity
- Trial name
- NCT05114018
- Testing
- Pasteurized A. muciniphila
- Where
- 2 sites in Germany, Ireland
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- A-Mansia Biotech S.A.
Hypertension, Atrial Fibrillation
Evaluation of a Non-Invasive Electrocardiogram-Assisted Blood Pressure Monitor
Approximately one billion people suffer from hypertension worldwide. At least 10% of this population, that is, 100 million people, also suffers from associated chronic conditions namely, atrial fibrillation (AF), obesity…
- Conditions
- Hypertension, Atrial Fibrillation, Obesity, Heart Failure
- Trial name
- NCT02053623
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- Health Parametrics Inc.
Healthy Participants, Overweight or Obese Participants
Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants
Clinical trials of IBI3040 with single-dose administration in healthy participants and multiple-dose administration in overweight or obese participants.
- Trial name
- NCT07765160
- Testing
- SAD: subcutaneous injection in the abdomen, MAD: subcutaneous injection in the abdomen
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity, Overweight
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- ATTAIN-2 (NCT05872620)
- Testing
- Orforglipron
- Where
- 136 sites in United States, Argentina and 9 more
- Volunteers
- 1,613 people
- Sponsor
- Eli Lilly and Company
Overweight or Obesity
Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects
This study aims to compare the relative bioavailability, safety and tolerability of the first-generation and second-generation formulations of HRS9531 tablets, as well as to explore the safety, tolerability and pharmacokinetic…
- Trial name
- NCT07150962
- Testing
- HRS-9531 Tablet
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Diabetes, Metabolism and Nutrition Disorder
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
This trial is conducted in Europe. The aim of the trial is to investigate the effect of semaglutide on energy intake, appetite sensations, postprandial glucose and triglyceride metabolism and gastric emptying in obese subjects…
- Conditions
- Diabetes, Metabolism and Nutrition Disorder, Obesity
- Trial name
- NCT02079870
- Testing
- semaglutide
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Blood Pressure
A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects
The study is being conducted to evaluate the effect of VI-0521 (Qsymia®) on blood pressure as measured by 24-hour ambulatory blood pressure monitoring, compared to both placebo and an active control (phentermine 30 mg).
- Trial name
- NCT05215418
- Testing
- VI-0521, Phentermine
- Where
- 28 sites in United States
- Volunteers
- 565 people
- Sponsor
- VIVUS LLC
Obesity, Overweight
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT07215559
- Testing
- Macupatide, Eloralintide
- Where
- 42 sites in United States, Argentina and 2 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Prader-Willi Syndrome
Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome
The primary objective of this study is to assess the efficacy of cannabidiol oral solution on hyperphagia-related behavior in patients with Prader-Willi Syndrome (PWS).
- Trial name
- NCT02844933
- Testing
- Cannabidiol
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Type 2 Diabetes, Obesity
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk.
- Conditions
- Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight
- Trial name
- ACHIEVE-4 (NCT05803421)
- Testing
- Orforglipron, Insulin Glargine
- Where
- 358 sites in United States, Argentina and 14 more
- Volunteers
- 2,749 people
- Sponsor
- Eli Lilly and Company
Overweight
Efficacy Study for SD Device
The purpose of this study is to determine whether the SD unique device is effective in treatment of overweight and obesity.
- Trial name
- NCT01534325
- Testing
- SD, Control
- Where
- 2 sites in Israel
- Volunteers
- 150 people
- Sponsor
- Beck Medical Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.